The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List


Mon, Apr 14, 9:00 AM, Zacks
Pharmacyclics (PCYC) Crumbles: Stock Falls by 7.7% - Tale of the Tape
Pharmacyclics’ shares fell by nearly 8% yesterday, continuing its downtrend in the past one-month time frame.

Wed, Apr 9, 10:46 AM, Zacks
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.

Pharmacyclics, Inc. (PCYC)

Pharmacyclics is a biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Co. has three proprietary drug candidates under clinical development and several preclinical lead molecules: an inhibitor of Bruton's tyrosine kinase (BTK) ibrutinib in several Phase III studies in hematologic malignancies, a BTK inhibitor lead optimization program targeting anti-inflammatory and autoimmune indications, an inhibitor of Factor VIIa in a Phase II clinical trial in pancreatic cancer and a histone deacetylase inhibitor, abexinostat, in Phase I and II clinical trials in solid tumors and hematological malignancies.

Company Name:  Pharmacyclics, Inc.
Sector:  Biotechnology
Number of ETFs Holding PCYC:  21
Total Market Value Held by ETFs:  $141.52M
Total Market Capitalization:  $6.66B
% of Market Cap. Held by ETFs:  2.13%
April 17, 2014    3:28 AM Eastern

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Trade PCYC Now:

Buy (3.31 out of 4)
66th percentile
(ranked higher than approx. 66% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Pharmacyclics, Inc. (PCYC) Page | The Online Investor | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.